Stereotactic Arrhythmia Radiotherapy for refractory ventricular tachycardia showed six manageable severe adverse events and no treatment-related deaths in long-term follow-up.
Is Stereotactic Arrhythmia radiotherapy safe during long-term follow-up in patients with refractory ventricular tachycardia?
Stereotactic arrhythmia radiotherapy for refractory ventricular tachycardia appears to have a manageable long-term safety profile, though routine echocardiographic monitoring for valvular dysfunction and pericardial effusion is recommended.
During long-term follow-up, six manageable treatment-related severe AEs were observed, while no treatment-related deaths occurred. Although no STAR-specific dose guidance could yet be defined, routine echocardiographic follow-up focused at valvular dysfunction and pericardial effusion are recommended. Larger, prospective studies are needed to further define the long-term safety profile of STAR and to develop evidence-based dose guidance and follow-up recommendations.
Hoeksema et al. (2026) studied this question. Stereotactic Arrhythmia Radiotherapy for refractory ventricular tachycardia showed six manageable severe adverse events and no treatment-related deaths in long-term follow-up.